RxDoctor Payments Data

Michael Eis, PhD

Psychiatry · Menomonee Falls, WINPI 1689653214

Payments from drug & device makers

$853in general payments, 2019–2025

Across 43 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$294
  • Neurocrine Biosciences, Inc.$162
  • AbbVie$138
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$110
  • Vanda Pharmaceuticals Inc.$51
  • E.r. Squibb & Sons, L.L.C.$47
  • plus $51 from 2 others

What the payments were for

  • Food & beverage$75989%
  • Education$9411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$853 in reported general payments places this provider in the 80th percentile of 543 psychiatry providers in Wisconsin.

See all psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$10,635
Medicare patients
53
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate86$279,102
IngrezzaValbenazine Tosylate23$188,645
Invega TrinzaPaliperidone Palmitate18$172,486
AristadaAripiprazole Lauroxil38$105,072
AustedoDeutetrabenazine12$66,232
Abilify MaintenaAripiprazole18$50,822
FanaptIloperidone12$41,138
VraylarCariprazine Hcl24$34,107
Paliperidone ErPaliperidone71$22,255
Olanzapine245$21,707
LybalviOlanzapine/Samidorphan Malate14$20,937
CaplytaLumateperone Tosylate11$17,489
VyvanseLisdexamfetamine Dimesylate25$14,300
Lurasidone Hcl80$14,203
SeroquelQuetiapine Fumarate14$10,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$25$451,588104 claims
Neurocrine Biosciences, Inc.Ingrezza$162$188,64523 claims
Alkermes, Inc.Aristada, Lybalvi$294$126,00952 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$26$50,82218 claims
Vanda Pharmaceuticals Inc.Fanapt$51$41,13812 claims
AbbVieVraylar$138$34,10724 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$110$17,48911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 543 psychiatry providers in Wisconsin.

Other psychiatry in Menomonee Falls

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →